Sufferers with beforehand handled, regionally superior or metastatic hormone receptor (HR)-positive, HER2-negative breast most cancers skilled superior progression-free survival when handled with the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT; SKB264; MK-2870) in contrast with chemotherapy, medical trial outcomes have proven.
Up to date findings from the part 3 OptiTROP-Breast02 trial had been offered on the 2025 ESMO Congress in Berlin.
Notably, sac-TMT elicited a 65% discount within the danger of illness development or loss of life versus chemotherapy and confirmed a constant profit throughout subgroups. At a median follow-up of seven.4 months, the median PFS (mPFS) in sufferers receiving sac-TMT (8.3 months) was roughly twice that of sufferers receiving chemotherapy (4.1 months).
Glossary
Development-free survival (PFS): the size of time an individual lives with most cancers with out the most cancers getting worse.
General survival (OS): the proportion of individuals in a research who’re nonetheless alive after a sure time period.
Goal response charge (ORR): the proportion of sufferers in a research whose most cancers shrinks or disappears after remedy.
Illness management charge (DCR): the proportion of sufferers in a research whose most cancers both shrinks, disappears, or stays steady with remedy.
Length of response (DOR): the size of time a affected person continues to have a response to a remedy with out the most cancers progressing.
ECOG efficiency standing: a scale that docs use to explain a affected person’s basic well-being and the way succesful they’re of performing peculiar every day duties.
Anemia: a situation the place your physique doesn’t have sufficient wholesome crimson blood cells to hold ample oxygen to your tissues, typically resulting in fatigue.
Neutropenia: a situation during which an individual has a low variety of neutrophils, that are a selected kind of white blood cell necessary for combating an infection.
Stomatitis: a basic time period for irritation or soreness contained in the mouth, which might embrace mouth sores.
Moreover, an interim evaluation of general survival (OS) revealed a constructive pattern amongst these receiving sac-TMT in comparison with these receiving chemotherapy.
“The present chemotherapy choices [for HR-positive/HER2-negative breast cancer] present restricted efficacy,” stated Man Li, professor on the Second Affiliated Hospital of Dalian Medical College, throughout the presentation. “Sac-TMT has proven promising exercise in pretreated sufferers with HR-positive/HER2-negative metastatic breast most cancers in [a] part 2 research.”
These new statistically vital and clinically significant efficacy knowledge from OptiTROP-Breast02, together with an noticed manageable security profile, strengthen the case for sac-TMT as a possible new remedy possibility for this affected person inhabitants who comprise a overwhelming majority of worldwide breast most cancers instances.
“The OptiTROP-Breast02 research helps sac-TMT as a brand new remedy possibility for sufferers with HR+/HER2– breast most cancers following endocrine-based remedy and chemotherapy,” stated Li.
What Is the Design of OptiTROP-Breast02?
OptiTROP-Breast02 is a worldwide randomized open-label research evaluating the efficacy and security of sac-TMT versus investigator’s selection of chemotherapy (ICC) in grownup sufferers with unresectable, regionally superior or metastatic HR-positive/HER2-negative breast most cancers who had failed no less than one line of systemic chemotherapy. The research is assessing the first finish level of PFS, together with secondary finish factors of investigator-assessed OS, goal response charge, illness management charge and period of response.
Sufferers had been eligible for participation if they’d HR-positive/HER2-negative breast most cancers, had between one and 4 traces of chemotherapy, and had no less than one endocrine remedy, CDK 4/6 inhibitor and taxane in any setting. Of 399 sufferers randomized to both the investigational arm (200 sufferers) or management arm (199 sufferers), 200 acquired 5 mg/kg of intravenous sac-TMT each 2 weeks, whereas 196 acquired ICC together with eribulin, capecitabine, gemcitabine and vinorelbine.
What Had been the Affected person Traits within the OptiTROP-Breast02 Trial?
Affected person traits had been properly balanced between the research arms. Throughout each arms, the median age was 54 years, two-thirds had an ECOG efficiency standing of 1, about 53% had been HER2 zero and 47% had been HER2 low. About 96% of sufferers had visceral metastases and over three-fourths had liver metastases. About three-fourths of sufferers had acquired neoadjuvant chemotherapy and all sufferers had acquired prior taxane, endocrine remedy and a CDK 4/6 inhibitor. About 56% of sufferers had acquired no less than two traces of chemotherapy within the superior/metastatic setting and somewhat over one-fourth of sufferers had main endocrine resistance.
What Was the Security Profile of Sac-TMT?
This most up-to-date report of security knowledge revealed a manageable security profile, with no new security indicators. When it comes to treatment-related unwanted side effects, the incidence of all-grade and no less than grade 3 (extreme) treatment-related unwanted side effects was comparable between investigational and management arms. The commonest treatment-related unwanted side effects for each sac-TMT and chemotherapy had been hematologic toxicities, together with decreased white blood cell rely, anemia and neutropenia. Whereas stomatitis was extra frequent in sufferers receiving sac-TMT (63% versus 8%), Li famous that these unwanted side effects had been primarily low-grade and manageable.
Therapy discontinuation occurred in 87 and 138 sufferers within the investigational and management arms, respectively. The commonest purpose for discontinuation was radiographic illness development in each the investigational arm (80 sufferers) and management arm (122 sufferers).
What Are the Subsequent Steps With Sac-TMT?
Relating to subsequent steps Li stated, “Section 3 research of sac-TMT as a monotherapy and/or together with Keytruda (pembrolizumab) in sufferers with chemotherapy-naïve HR-positive/HER2-negative breast most cancers are ongoing globally and in China.”
REFERENCES:
“Sacituzumab tirumotecan (sac-TMT) vs investigator’s selection of chemotherapy (ICC) in beforehand handled regionally superior or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast most cancers (BC): outcomes from the randomized, multi-center part 3 OptiTROP-Breast02 research” by Man Li, offered at: ESMO 2025 Congress; October 17–20, 2025; Berlin Germany. Summary LBA23.
For extra information on most cancers updates, analysis and training,
